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Abstract
Background: Primary open-angle glaucoma (POAG) is the most common form of glaucoma which
is an irreversible blind leading disease and lacks effective remedies. In recent years, POAG has been
linked to the gene MYOC encoding myocilin that has been identified to harbor causal mutations. A
variety of studies show that the mutant myocilin acts by gain of function. The mutant MYOC protein
induces endoplasmic reticulum (ER) stress and the resultant unfolded protein response (UPR)
induces apoptosis in the trabecular meshwork cells, which then leads to an increase in resistance
to aqueous humor outflow, elevated intraocular pressure (IOP), and, ultimately, glaucoma.
Culturing human trabecular meshwork (HTM) cells at a condition facilitating protein folding
promotes secretion of mutant myocilin, normalizes cell morphology and reverses cell lethality.
Presentation of the Hypothesis: We speculate that a complete elimination of mutant myocilin
expression in trabecular meshwork cells is safe and that gives the possibility of avoiding the POAG
phenotype.
Testing the Hypothesis: We propose RNA interference (RNAi) as a gene silencing therapy to
eliminate the mutant myocilin proteins in the trabecular meshwork cells, either in a mutation-
dependent or mutation-independent way due to the different engineering of the small interfering
(si) RNA.
Implications of the Hypothesis: The RNAi strategy can reverse the pathological process of
trabecular meshwork cells and thus treat the POAG caused by myocilin gene mutation. This
strategy can also be applicable to many protein-misfolding diseases caused by gain-of-function
mutant proteins.
Background
Glaucoma is a group of progressive optic neuropathies
that have in common a slow progressive degeneration of
retinal ganglion cells and their axons, resulting in a dis-
tinct appearance of the optic disc and a concomitant pat-
tern of visual loss[1]. Without adequate treatment,
glaucoma can progress to irreversible visual disability and
eventual blindness [1]. Of the many types of glaucoma,
primary open angle glaucoma (POAG) is perhaps the
most common, particularly in populations of African
ancestry and European [2-4]. In most cases of POAG,
increased resistance to the outflow of aqueous humor
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tually leads to loss of retinal ganglion cells[5]. Though
Increased IOP has been proven to be the only treatable
risk factor for glaucoma, the biological basis of the disease
is not yet fully understood[1]. This may underlies that the
present treatment of POAG directed at lowering IOP[6]
does not seem to halt all cases of progression [7-10]. To
date, six loci (GLC1A-E) have been linked to POAG alone.
Among them, the gene MYOC encoding myocilin has
been identified as harboring causal mutations, which are
responsible for 3-4% adult-onset POAG cases [11]. This
warrants the gene therapy which holds the promise for
curing the disease. Current investigations of gene therapy
mainly focus on the transfer and expression of genes
encoding IOP-lowering, neuroprotective gene products,
and/or, wound healing inhibitors[12], but do not really
emphasize a specific elimination of the causal mutant
proteins. Here we propose RNA interference (RNAi) as
gene silencing therapy for complete elimination of
mutant myocilin from human trabecular meshwork
(HTM) cells.
Presentation of Hypothesis
The human myocilin gene encodes a 504 amino acid glyc-
oprotein expressed extra- or intracellularly in almost every
ocular tissue[13,14] but predominantly in the trabecular
meshwork [15]which is a tissue provides major resistance
to the aqueous humor outflow pathway, and the tissue
involved in elevated IOP associated with glaucoma. How-
ever, MYOC-null individuals (no matter mice [16] or
human beings [17,18] have normal eyes and intraocular
pressure. These individuals are both viable and fertile as
well [16-18]. Overexpression of wild type (WT) MYOC in
transgenic mice does not lead to any glaucomatous phe-
notype[19,20]. All these facts suggest that haploinsuffi-
ciency of MYOC is not a critical mechanism in the
pathogenesis of POAG [16-20].
A variety of recent studies show that the mutant myocilin
acts in the HTM cells by gain of function[16,21-27]. It was
observed that, in culture media, very little to no mutant
myocilin associated with the development of glaucoma
was secreted out of the HTM cells, while WT and polymor-
phism variant myocilin were secreted normally[26]. Fur-
ther investigations found that the disease-causing
myocilin mutants were actually misfolded, were highly
aggregation-prone and accumulated in large aggregates or
formed heteromeric complexes with WT myocilin in the
endoplasmic reticulum (ER)[5,22,24,28]. The ER is
responsible for the synthesis, modification and delivery of
correctly folded proteins to their proper target sites.
Increased expression of mutant, folding-incompetent pro-
teins causes ER stress and an ER stress response, called the
unfolded protein response(UPR). The UPR is an adaptive
mechanism to return the ER to its normal physiological
state by upregulating the ER folding capacity and down-
regulating the biosynthetic load of the ER. When the UPR
does not remedy the stress situation, apoptosis is initiated
in higher eukaryotic organisms, presumably to eliminate
unhealthy cells [29]. In the case of MYOC-associated
POAG, the aggregates induced the unfolded protein
response proteins BiP and phosphorylated endoplasmic
reticulum-localized eukaryotic initiation factor-2_ kinase
(PERK) with the subsequent activation of caspases 12 and
3 and expression of C/EBP homologous protein (CHOP)/
GADD153, leading to abnormal HTM cell morphology
and cell apoptosis[24,28]. The progressive loss of HTM
cells due to apoptosis should accordingly diminish the
phagocytotic capacity of the remaining TM cell popula-
tion to clean the outflow drainage and eventually results
in humor outflow resistance and elevated IOP[24]. This is
consist with the electron microscopic findings from biop-
sies of POAG patients showing a reduction of TM cells as
well as thickened trabeculae and accumulation of sheath-
derived plaques [30-33].
Since the mutant myocilin induces ER stress and eventu-
ally leads to the apoptosis of HTM cells and hence the
pathogenesis of Myoc- associated glaucoma, a complete
elimination of mutant myocilin in HTM cells may disrupt
or even partly reverse the disease. In support of this pro-
posal are two major previous investigation findings: (1)
Culturing HTM cells at a condition facilitating protein
folding promotes secretion of mutant myocilin, normal-
izes cell morphology and reverses cell lethality[5], and (2)
MYOC-null individuals have no glaucomatous phenotype
and are both viable and fertile as well [16-18].
Testing the Hypothesis
To eliminate the mutant myocilin in HTM cells, RNAi can
be used as a powerful gene silencing method [34-37],
either in a mutation-dependent [38] or a mutation-inde-
pendent way [39]. In mutation dependent RNAi, a cus-
tomized double-stranded small interfering (si) RNA
targeting a mutant sequence is synthesized and conducted
by a plasmid to the HTM cell expressing the very mutant
myocilin. The siRNA can be engineered specifically to sup-
press the mutant alleles differing from WT alleles as little
as only a single nucleotide[38], so that the WT myocilin
can express normally in the heterozygotes without being
insulted. However, myocilin-associated POAG is intra-
genic heterogeneous [40] and customized siRNA inhibi-
tion targeting large numbers of individual mutations
would be costly. A more economical approach of muta-
tion-independent silencing will avoid this drawback. In
this approach, siRNA complementary to the untranslated
regions (UTRs) of the target mRNA is conducted to the
HTM cell and hence both the WT and mutant alleles
would be suppressed. Moreover, a replacement WT myo-
cilin gene with modified UTRs that is sparing from thePage 2 of 4
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allowing the expression of WT alleles while suppressing
that of the mutant ones simultaneously[39]. In the case of
MYOC-associated POAG, the insertion of the replacement
WT myocilin gene may be unnecessary for suppression of
myocilin gene totally limited to HTM cells might not lead
to pathological phenotypes. If such a suppression without
inserting the replacement WT gene is safe, the mutation-
independent strategy would probably be the best choice
among the above proposals.
Implications of the Hypothesis
In this article, we propose RNAi as a gene silencing ther-
apy for the MYOC-associated POAG. It has been demon-
strated by abundant researches [5,22,24,28] that mutant
myocilin proteins are insufficiently folded and accumu-
late in the ER, inducing UPR with subsequently activated
cell apoptosis. We hypothesize that if these mutant pro-
teins are suppressed by siRNA mediated RNAi, the cell
lesion would be reversed. To the best of our knowledge,
our idea of treating POAG by inhibiting the disease caus-
ing gene has not been stated before. Those investigated
strategies of gene therapy for glaucoma do not aim at the
disease causing mutants, but focus on inducing genes
compensating for the defects [12], which are actually the
modifications of contemporary treatments at the gene
level. Compared with this, the RNAi strategy we propose
here is more specific to the etiological factor and would
likely to be more effective. Shinohara et al [41]proposed a
hypothesis of treating the retinitis pigmentosa (RP) by
silencing the mutant rhodopsin in a allele-specific way.
However, since MYOC-null individuals have been
reported to be healthy, we suspect that totally suppressing
the myocilin without inserting a replacement WT myoci-
lin to HTM cells would be safe and economically feasible.
ER retention of mutant proteins has been implicated in
the pathogenesis of many ER storage diseases other than
POAG, including some inherited neurodegenerative dis-
orders like Alzheimer's disease [29]. The RNAi strategy
aiming at eliminating the misfolded mutant proteins can
also be applied to these disorders. Problems to be solved
are the safety and efficiency of RNAi. A highly efficient
siRNA should be chosen from a variety of candidates and
the side effects should be observed with caution by a series
of investigations before it can be carried out clinically.
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